Boston Scientific Makes Q2 Profit Gains

Marlborough, Mass.-based Boston Scientific Corp. generated sales of $1.84 billion during the second quarter (ended June 30) compared to the company’s guidance range for the quarter of $1.80 billion to $1.85 billion.  This represents 6 percent operational revenue growth (constant currency basis, excluding divested businesses) and a decrease of 2 percent on a reported basis, all compared to the prior year period.

The company achieved adjusted earnings per share of 22 cents for the period, compared to 21 cents a year ago, and GAAP earnings of $102 million, or approximately 8 cents per share, compared to flat growth a year ago.

“Our strong performance in the second quarter reflects the consistent execution of our global teams,” said Mike Mahoney, president and CEO. “We are particularly pleased with the improved growth in MedSurg and continued strength in Cardiovascular.  We look forward to continued momentum with several ongoing product launches and the planned closing of the American Medical Systems urology portfolio acquisition in the third quarter of 2015.”

The company reported second quarter revenue growth of 10 percent in Cardiovascular, 7 percent in MedSurg, and remained flat in Rhythm Management, all on a constant currency basis over the prior year period.

Delivered operational revenue growth of 6 percent across all three major regions (United States, Europe, and Asia, Middle East and Africa) and 12 percent operational revenue growth in the emerging markets.